Literature DB >> 16034101

CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.

Julie M Roda1, Robin Parihar, William E Carson.   

Abstract

Bacterial DNA contains a high frequency of unmethylated CpG motifs that stimulate immune cells via TLR9. NK cells express a low-affinity activating receptor for the Fc portion of IgG (FcgammaRIIIa), but were not thought to express TLR9 protein. The direct response of NK cells to CpG oligodeoxynucleotides (ODN) in the presence of FcR stimulation was investigated. Human NK cells cultured in the presence of CpG ODN plus immobilized IgG or Ab-coated tumor cells secreted large amounts of IFN-gamma (>2000 pg/ml), whereas cells stimulated with Ab alone, CpG ODN alone, or Ab and control ODN produced negligible amounts. Enhanced secretion of IL-8, macrophage-derived chemokine, and MIP-1alpha was also observed after costimulation. NK cell cytokine production was not the result of interactions with APCs or their cytokine products. Flow cytometric analysis revealed that 36 +/- 3.5% of human NK cells expressed basal levels of TLR9. TLR9 expression in human NK cells was confirmed by immunoblot analysis. Only TLR9-expressing NK cells responded to CpG ODN and Ab, because cytokine production was not observed in NK cells from TLR9-deficient mice. Mice receiving CpG ODN and HER2/neu-positive tumor cells treated with an anti-HER2 Ab exhibited enhanced systemic levels of IFN-gamma compared with mice receiving either agent alone. TLR9-/- animals reconstituted with TLR9+/+ NK cells secreted IFN-gamma in response to CpG ODN and Ab-coated tumor cells. These findings indicate that CpG ODN can directly enhance the NK cell cytokine response to Ab-coated targets via activation of TLR9.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034101     DOI: 10.4049/jimmunol.175.3.1619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

2.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

3.  Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.

Authors:  Felix N Toka; Charles K Nfon; Harry Dawson; William T Golde
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

4.  Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation.

Authors:  Jeng-Ting Tsao; Song-Chou Hsieh; Bor-Luen Chiang; Chia-Li Yu; Shih-Chang Lin
Journal:  Clin Exp Med       Date:  2011-11-05       Impact factor: 3.984

5.  Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.

Authors:  Darya Alizadeh; Leying Zhang; Christine E Brown; Omar Farrukh; Michael C Jensen; Behnam Badie
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

6.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

Review 8.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

9.  A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

Authors:  Tanios S Bekaii-Saab; Julie M Roda; Kristan D Guenterberg; Bhuvanaswari Ramaswamy; Donn C Young; Amy K Ferketich; Tammy A Lamb; Michael R Grever; Charles L Shapiro; William E Carson
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

10.  Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Authors:  Kory L Alderson; Mitchell Luangrath; Megan M Elsenheimer; Stephen D Gillies; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.